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Abstract
We performed a retrospective analysis of 1156 patients affected by early breast cancer in order to estimate the
real incidence of patients with T1 tumors presenting > 2 metastatic lymph nodes. The advantage of axillary
surgery seems to be limited only to a speciﬁc subgroup of T1 patients who are undergoing conservative
surgery plus radiotherapy.
Background: The role of axillary surgery for early breast carcinoma treatedwith conservative surgery and radiotherapy is
currently the subject of considerable investigation. Recent studies have supported the noninferiority of avoiding axillary
surgery in terms of overall survival when sentinel lymph node biopsy (SLNB) presents  2 positive lymph nodes, thus
sparing the patients from complications. There are some ongoing studies investigating the possibility of omitting SLNB.
Axillary study seems to be sufﬁciently replaced by SLNB for staging the disease. Axillary surgery maintains a therapeutic
role in the presence of > 2 metastatic lymph nodes at SLNB. Patients and Methods: We performed a retrospective
analysis of 1156 patients with early breast cancer to estimate the real incidence of patients with T1 tumors presenting
> 2 metastatic lymph nodes. Results: Of the 1156 cases, only 106 (9.2%) had > 2 axillary metastatic lymph nodes.
More speciﬁcally, 38 (4.3%) of 884 T1 cases, and 6 (2.3%) of 257 of T1b cases had > 2 metastatic lymph nodes.
Conclusion: The advantage of axillary surgery seems to be limited only to a speciﬁc subgroup of T1 patients who are
undergoing conservative surgery plus radiotherapy. The ongoing studies on avoiding SLNB will likely prove the
noninferiority of omitting biopsy because these studies are conducted in the whole population of early breast cancers.
It is necessary to identify more accurately the subpopulation of patients who may beneﬁt from axillary surgery.
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The purpose of surgery for breast tumors is to improve overall
survival as well as to achieve local control of the disease and
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http://dx.doi.org/10.1016/j.clbc.2016.10.001breast carcinoma is based on conservative surgery tailored to the
volume of disease in association with whole-breast radiotherapy and
speciﬁc medical therapy. Sentinel lymph node biopsy (SLNB)
provides information regarding the lymph node spreading of the
tumor: if positive nodes are detected, the surgery is completed by
axillary lymph node dissection (ALND).
Axillary surgery for breast cancer is currently considered a staging
procedure that does not seem to inﬂuence breast cancer mortality,
although SLNB alone provides sufﬁcient information in the thera-
peutic setting. Moreover, ALND is burdened by complications that
negatively affect quality of life.
Several studies have suggested that ALND could be an over-
treatment, even in the case of positive sentinel lymph node (SLN).
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Table 1 Patient Characteristics
Characteristic Value
Total No. of Cases 1156
T1 884
T2 257
Median age (years) 57.2 (29-85)






ER ND 26 (2.3%)
PRþ 828 (71.6%)
PR 302 (26.1%)
PR ND 26 (2.3%)
HER-2 0 212 (18.2%)
HER-2 1þ 553 (47.9%)
HER-2 2þ 226 (19.6%)
HER-2/HER-2 3þ 121 (10.5%)
HER-2 ND 44 (3.8%)
Abbreviations: ER ¼ estrogen receptor; G ¼ grade; HER-2 ¼ human epidermal growth factor
receptor 2; ND ¼ not determined; PR ¼ progesterone receptor.
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Author's Personal CopyZ0011 trial found that for clinically negative lymph node tumors
(T1/T2 N0 M0) with SLN metastases in  2 nodes, ALND can be
safely avoided, and surgeons are still provided with adequate
information to permit surgical staging and comparable locoregional
control and survival.1
Another trial (International Breast Cancer Study Group
[IBCSG] 23-01)2 conducted on patients with micrometastatic
SLN positivity and tumor < 5 cm in size demonstrated the
noninferiority of avoiding ALND, thus sparing the patient from
the complications of axillary surgery. A randomized clinical trial by
Agresti et al3 performed on T1N0 breast cancers supported the
noninferiority, in selected groups of low-risk patients and in terms
of overall survival, of breast-conservation surgery without ALND
compared to breast conservation plus ALND. The 2014 American
Society of Clinical Oncology and 2015 St Gallen 2015 guidelines
now suggest that ALND may be omitted in selected patients with
1 to 2 positive SLNs who are undergoing conservative surgery and
radiotherapy without affecting survival or risk of local recur-
rence.4,5 The SOUND (Sentinel node vs. Observation after axil-
lary Ultra-SouND) trial is currently ongoing to evaluate SLNB
with or without ALND versus no axillary surgical staging.6 Also
ongoing is the Intergroup-Sentinel-Mamma (INSEMA) trial,
which is testing the noninferiority of no axillary surgery compared
to SLNB.7
Because avoiding ALND is to be considered safe when SLNB
presents  2 positive lymph nodes, the obvious question that arises
is, how many patients who undergo conservative surgery have > 2
metastatic axillary lymph nodes? This group of patients could
possibly beneﬁt from ALND given the absence of beneﬁts when
metastatic axillary lymph nodes are  2.
The aim of this study was to retrospectively evaluate a population
of patients with early breast cancer treated with a conservative
approach to obtain cases of > 2 metastatic axillary lymph nodes
after ALND.
Patients and Methods
We retrospectively evaluated a cohort of 1156 consecutive
women with early breast cancer (2 patients had bilateral carcinoma)
between January 2001 and December 2013. All patients underwent
breast-conserving surgery and SLNB; when the SLNB results were
positive, axillary dissection was performed. After surgery, all patients
were treated by external-beam radiotherapy on the whole breast
through 2 tangential ﬁelds (50 plus 10 Gy as a boost to the tumor
bed) with a linear accelerator. We evaluated the number and per-
centage of patients with positive SLN, patients with positive SLN
treated with ALND, patients with negative axillary lymph nodes
after ALND, and, globally, the percentage of patients with > 2
metastatic axillary lymph nodes. According to the tumor, node,
metastasis classiﬁcation system, SLNs with micrometastasis were
considered positive and SLNs with isolated tumor cells negative.
Results
The median age of patients was 57.2 years (range, 29-86 years).
The average tumor diameter was 16 mm, with a median of 15 mm.
Patient characteristics are summarized in Table 1. A total of 648
patients had SLN localization by radiocolloid, 248 by blue dye, and
262 by combined techniques, as previously reported.8,9 Of 1156Clinical Breast Cancer April 2017cases, 884 were of T1 disease and 272 T2 disease. SLNB results
were negative in 770 cases (66.6% of cases) and metastatic in 386
(33.4%). Of the latter, in 283 cases (24.5%) there was a macro-
metastasis and in 103 cases (8.9%) a micrometastasis. A total of 380
of 386 patients with metastatic SLN underwent ALND; in 234
patients (61.6%), the axilla results were negative. Overall, 274
patients had  2 metastatic lymph nodes and 106 (9.2%) had > 2
metastatic lymph nodes (Table 2). Considering only the 884 T1
tumors (Table 2), SLNB results were negative in 650 cases (73.5%)
and metastatic in 234 (26.5%); of these, 166 (18.8%) were mac-
rometastasis and 68 (7.7%) micrometastasis. ALND was performed
in 233 of 234 cases of positive SLNB; histology was negative for
166 cases (71.3%). Therefore, only 38 (4.3%) of 884 T1 patients
had > 2 axillary metastatic lymph nodes. Instead, SLNB results
were negative in 199 (77.4%) of 257 T1b patients, and metastatic
disease occurred in 35 patients (13.6%).
In 35 patients who underwent ALND, results were negative in 24
patients (68.6%). In only 6 (2.3%) of 257 T1b patients did the
axilla contain > 2 metastatic lymph nodes.
Discussion
If we accept the premise that axillary surgery offers a real
advantage to patients who undergo conservative surgery and
radiotherapy and who present with > 2 metastatic axillary lymph
nodes, then according to the data obtained from this unselected
population, it emerges that the majority of T1 patients with positive
SLNB results were overtreated by axillary surgery. Only 4.3% of T1
patients had > 2 metastatic lymph nodes and thus obtained beneﬁt
from extending surgery to the axilla; this percentage decreased to
2.3% for T1b patients. The limitation is that these results come





Micrometastasis ALNDL LND £2 at ALND LND >2 at ALND
Total (n ¼ 1156) 770 (66.6%) 283 (24.48%) 103 (8.84%) 234/380 (61.6%) 270 (23.3%) 106 (9.2%)
T1 (n ¼ 884) 650 (73.5%) 166 (18.8%) 68 (7.7%) 166/233 (71.5%) 194 (22.2%) 38 (4.3%)
T1b (n ¼ 257) 199 (74.4%) 25 (9.7%) 10 (3.9%) 24/35 (68.6%) 29 (11.3%) 6 (2.3%)
Abbreviations: ALND ¼ axillary lymph node dissection; LN ¼ lymph node; SLN ¼ sentinel lymph node.
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randomized population. Our results come from a single-center,
single-surgical-team experience. The patients were not selected;
some were symptomatic at the time of discovery of the disease, and
some came to us as a result of cancer screening campaigns. This
population therefore reﬂects the real incidence of disease in the
general population. SLN evaluation still marks a watershed in the
management of early breast carcinoma.
SLNB has resulted in an improvement in the quality of life of
patients who undergo breast surgery by reducing the complications
that may arise from nonselective axillary surgery.10 Initial contra-
indications, such as multifocal and multicentric tumor or previous
excisional biopsy, have been eliminated.11,12 Furthermore, there is
improved understanding regarding the lymphatic drainage of the
breast into the axillary lymph nodes. The progression and metastatic
spreading of tumor is now known to occur in a stepwise, continuous
fashion from the periphery of the axilla in 97.4% of patients, and
only in 2.6% of cases does it involve axillary level II, skipping
axillary level I.13
The Axillary Lymphatic Mapping Against Nodal Axillary Clear-
ance (ALMANAC) trial14 found that women who underwent
SLNB alone experienced less lymphedema and sensory deﬁcit than
did women who underwent ALND. In addition, the women were
also able to resume their normal daily activities more quickly than
women who underwent ALND.15,16
Some criticisms had been leveled at the ACOSOG Z0011 trial
resulting from the “favorable” nature of the disease in the enrolled
randomized patients, where only 27% of the patients had additional
metastatic nodes after ALND, compared to a higher percentage in
other studies. Moreover, the younger population and those with
estrogen receptorenegative tumors were insufﬁcient in number to
consider avoidance of ALND a safe prospect for this group.
These criticisms, however, do not detract from the value of this
landmark trial.
Dengel et al,17 in a prospective study designed to determine how
often ALND can be avoided in patients meeting ACOSOG Z0011
eligibility criteria, reported that 84% of patients, not selected on the
basis of age, tumor characteristics, axillary imaging, or nomogram
predictions, were found to have metastases in  2 axillary nodes,
thus suggesting that these patients had a low axillary tumor burden.
The role of SLNB is currently under investigation, given the
reduced information coming from the axillary status and as a result
of the emerging role of tumor biology in the choice of tailored
therapy. A randomized multicenter trial is underway in patients
with a negative preoperative axillary assessment, tumor  2 cm, and
patients eligible for conservative surgery to evaluate SLNB with or
without axillary dissection versus observation (no axillary surgicalstaging).6 The primary end point of the trial is disease-free survival.
The results obtained from the preliminary analysis regarding the
impact of different types of surgery on postoperative physical
function and symptoms of the ipsilateral upper limb are that SLNB
signiﬁcantly worsens early postoperative physical function and
symptoms of ipsilateral upper limb compared to no surgery of the
axilla. This ﬁnding is limited to the ﬁrst week after the operation
and is no longer present at 6 and 12 months.18
The routine assessment of the axilla by means of ultrasound,
combined with ﬁne-needle biopsy, has reduced the rate of positive
SLNBs19,20 and has enabled the identiﬁcation of patients with
axillary metastases who require ALND. A retrospective study of
1140 patients (T1/T2) at the Mayo Clinic in Rochester, Minnesota
(all of whom were negative for axillary ultrasound and ﬁne-needle
aspiration), reported 13% of patients to be SLNB positive. Only
3% of patients had  3 positive SLNs.21 The reported SLN posi-
tivity rate of < 20% in patients with early breast cancer in the era of
mammograms raises questions about that same role for SLNB, and
consequently the need for performing ALND when the SLNB is
positive and the patient is receiving adjuvant treatment (radio-
therapy or medical therapy).
Radiotherapy actively contributes to the success of the conser-
vative approach. The AMAROS (Radiotherapy or Surgery of the
Axilla After a Positive Sentinel Node in Breast Cancer) trial found
that ALND and axillary radiotherapy after a positive SLNB ﬁnding
provided excellent and comparable axillary control for patients with
T1-2 primary breast cancer and no palpable lymphadenopathy, but
that radiotherapy provided signiﬁcantly less morbidity.22 It is
recognized that whole-breast radiotherapy decreases the regional
recurrence rate of tumors, most likely caused by accidental irradi-
ation of part of the axilla. In fact, the lower part of the axilla is
currently irradiated and receives a nearly therapeutic dose,
depending on the upper limit of the tangential ﬁelds to the breast or
chest wall.23 A meta-analysis by van Wely et al24 showed that
external-beam radiotherapy to the breast was associated with a lower
axillary recurrence rate compared to that in patients who did not
receive it as part of initial therapy. Although it may not be
considered therapeutic,25 the dose delivered to the region in which
the SLNs are normally found could well inﬂuence the natural
evolution of residual tumor cells.
The presence of lymph node metastases does not necessarily
imply a further clinically evident development of the disease. The
National Surgical Adjuvant Breast and Bowel Project (NSABP)
B-04 trial demonstrated that less than half of the patients with
occult nodal metastases developed clinically detectable lymph nodes.
None of the patients received adjuvant systemic therapy.26 Systemic
therapy plays a key role in achieving low regional recurrence rates.Clinical Breast Cancer April 2017 - e55
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Author's Personal CopyAdjuvant systemic therapy signiﬁcantly reduces locoregional recur-
rence,27-29 and neoadjuvant medical therapy can eradicate axillary
lymph node metastases.30
The subtypes may be predictive of locoregional recurrence
and survival even after postmastectomy radiotherapy and neo-
adjuvant chemotherapy.31-33 In a meta-analysis conducted by
Lowery et al,34 locoregional recurrence rates varied between
different subtypes. In particular, luminal tumors exhibited the
lowest rates of local recurrence. Patients with triple-negative and
HER-2/neueoverexpressing breast tumors were at increased risk of
developing local recurrence after conservative surgery or mastec-
tomy. Furthermore, several studies have suggested that the triple-
negative tumor subtype may predict a lower risk of nodal involve-
ment.35-39 Because biology and systemic therapy inﬂuence the
natural evolution of disease, the indications for axillary surgery
should take these factors into consideration.
Single-center studies do not demonstrate any beneﬁts in per-
forming axillary surgery, but meta-analyses lead to a different
conclusion. A recent meta-analysis shows an advantage of axillary
surgery both for overall survival and recurrence-free survival.40 It
was conducted on patients with operable primary breast cancer to
determine the clinical impact of ALND in the treatment of invasive
breast cancer. ALND seems to positively affect overall and
recurrence-free survival from breast cancer.
Another meta-analysis concluded that for patients with micro-
metastasis at SLN, SLNB alone is noninferior to completion
ALND. For patients with macrometastases to the axilla, omitting
ALND may also be considered a feasible option, provided that the
patients receive appropriate systemic chemotherapy and hormone
therapy. However, this should be considered with caution because
this meta-analysis had a smaller number of patients with a macro-
metastatic sentinel node.41
A large review conducted on patients with 1 to 2 metastatic
lymph nodes who underwent SLNB or ALND showed an increase
of breast cancerespeciﬁc survival limited to patients younger than
50 years old with hormone receptorenegative tumors who under-
went ALND.42 It seems that only some subgroups of patients draw
beneﬁt from ALND, not the entire population.
Conclusion
The real advantage of axillary surgery in patients who are
undergoing conservative surgery with whole-breast radiotherapy
appears limited to those with > 2 metastatic lymph nodes (ie, only
4.3% of T1 tumor cases, according to our data).
Currently ongoing trials such as SOUND and INSEMA,6,7
because they are conducted on the entire population of early
breast cancers, may lack a sufﬁcient number of events and conse-
quently will demonstrate the noninferiority in avoiding ALND. By
considering the other emerging factors42,43 that inﬂuence survival
after ALND in breast carcinoma, such studies should investigate
speciﬁc subgroups, not the entire population of patients.
Clinical Practice Points
 This study retrospectively investigated the real incidence of early
breast cancers (treated with conservative surgery plus radio-
therapy) presenting > 2 metastatic lymph nodes after axillary
surgery.Clinical Breast Cancer April 2017 The role of axillary lymph node surgery is under investigation
because SLNB is sufﬁcient to stage the disease.
 Axillary surgery is burdened with complications that affect
quality of life.
 Recent studies have demonstrated that ALND might be safely
avoided if SLNB presents  2 positive lymph nodes.
 The real advantage of axillary surgery seems to be limited only to
a speciﬁc subgroup of T1 patients who are undergoing conser-
vative surgery plus radiotherapy.
 The role of SLNB is under investigation; ongoing trials have
demonstrated the noninferiority of omitting this procedure.
However, these trials are directed to the entire population and
thus will likely conﬁrm this hypothesis.
 We think that these studies should be conducted for speciﬁc
subgroups of patients (according to the biology of the tumor and
other emerging factors that affect tumor behavior) to determine
who will receive beneﬁt from axillary dissection.Acknowledgment
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